TRANSCODE THERAPEUTICS INC
RNAZNASDAQTrading Snapshot
- Day Range
- $587.40 – $592.95
- 52-Week Range
- $1.58 – $20.99
- Volume
- $3.17B
- Avg Volume
- $2.73B
- Shares Outstanding
- 1.1M
- Next Earnings
- Dec 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $153,390
- Last Q Revenue
- $41,530
- P/E Ratio
- -0.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-45.65
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +157.5%
Why Investors Own RNAZ
- ✓High-growth profile — revenue up +39.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 67% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
TRANSCODE THERAPEUTICS INC
RNAZ
StockOtter · stockotter.spaceAbout TRANSCODE THERAPEUTICS INC
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
TRANSCODE THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift RNAZ price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
TRANSCODE THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.